Healio compiled a list of the most-read FDA approvals in dermatology in 2024. The top approval was Zelsuvmi for molluscum contagiosum, followed by Xeomin, Klisyri, Zoryve, and others. Zelsuvmi is a topical antiviral gel for viral skin infections in children. Xeomin was approved for facial lines, Klisyri for actinic keratosis on larger areas, Zoryve for atopic dermatitis, and Selarsdi as a biosimilar for psoriasis and psoriatic arthritis. Other approvals include Leqselvi for alopecia areata, NexoBrid for thermal burns in children, Emrosi for rosacea, Sofdra gel for hyperhidrosis, and Bimzelx for hidradenitis suppurativa.
Source link
Zelsuvmi approval tops this year’s most-read FDA approvals in dermatology
